Senti Biosciences (NASDAQ:SNTI) Shares Down 3.8% – Time to Sell?

Senti Biosciences, Inc. (NASDAQ:SNTI)’s stock price traded down 3.8% on Tuesday . The stock traded as low as $0.9057 and last traded at $0.9057. 178,419 shares traded hands during mid-day trading, a decline of 12% from the average session volume of 202,477 shares. The stock had previously closed at $0.9416.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the stock. Chardan Capital boosted their target price on shares of Senti Biosciences from $11.00 to $12.00 and gave the company a “buy” rating in a report on Friday, May 15th. Weiss Ratings reissued a “sell (e+)” rating on shares of Senti Biosciences in a research note on Tuesday, April 21st. Finally, Wall Street Zen raised shares of Senti Biosciences from a “strong sell” rating to a “hold” rating in a research note on Saturday, March 28th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $10.00.

Senti Biosciences Stock Performance

The business’s 50 day moving average price is $0.97 and its 200-day moving average price is $1.09. The firm has a market capitalization of $30.67 million, a PE ratio of -0.51 and a beta of 2.08.

Senti Biosciences (NASDAQ:SNTI) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.22. The company had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.02 million. As a group, analysts anticipate that Senti Biosciences, Inc. will post -1.53 earnings per share for the current year.

Institutional Investors Weigh In On Senti Biosciences

Large investors have recently added to or reduced their stakes in the business. Jane Street Group LLC purchased a new stake in Senti Biosciences during the 4th quarter worth approximately $40,000. Citadel Advisors LLC purchased a new stake in Senti Biosciences during the 3rd quarter worth approximately $117,000. Armistice Capital LLC purchased a new stake in Senti Biosciences during the 2nd quarter worth approximately $1,883,000. Geode Capital Management LLC increased its stake in Senti Biosciences by 395.6% during the 2nd quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock worth $311,000 after buying an additional 117,588 shares during the period. Finally, Virtu Financial LLC purchased a new stake in Senti Biosciences during the 4th quarter worth approximately $46,000. 25.70% of the stock is owned by hedge funds and other institutional investors.

Senti Biosciences Company Profile

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.